IRulya Therapeutics Inc.
IRLA· Nasdaq
IRLAIRulya Therapeutics Inc.
Filed Aug 9, 2022 · 10-Q · 40 days after period end · 0000950170-22-016102
| Metric | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 |
|---|---|---|---|---|
| Net Income | -$16.56M | -$21.75M | -$17.61M | -$9.06M |
| EPS Diluted | -$0.51 | -$0.74 | -$0.60 | -$0.57 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IRulya Therapeutics Inc. · CIK 1662774 · Engraved from SEC EDGAR
ended Jun 30, 2022 · filed Aug 9, 2022 · 40 d after period end
